Literature DB >> 31809559

Trajectories of returning to work and its impact on survival in survivors with oral cancer: A 5-year follow-up study.

Yuan-Yuei Chen1,2,3, Chung-Ching Wang2,4, Wei-Te Wu5, Ching-Huang Lai6, Ching-Liang Ho7, Ya-Yuan Hsu8, Wei-Liang Chen2,4.   

Abstract

BACKGROUND: A return to work (RTW) is a challenge for survivors of oral cancer. Further light could be shed on the RTW of patients with oral cancer, which remains largely uninvestigated. The objective of this study was to investigate the trajectories of RTW and their impact on survival in workers with oral cancer.
METHODS: In total, 12,222 workers who were newly diagnosed with oral cancer were identified during the period from 2004 to 2015 and were included in this cohort study. The associations between independent variables and RTW were analyzed using Cox proportional hazard models.
RESULTS: Overall, 8793 workers returned to work in the first years after a diagnosis of oral cancer. Chemotherapy (hazard ratio [HR], 0.88; 95% CI, 0.78-0.99) and radiation therapy (HR, 0.83; 95% CI, 0.75-0.92) were inversely associated with RTW. Patients who had received surgical treatment (HR, 1.24; 95% CI, 1.01-1.53) were more likely to RTW. Employees with stage I (HR, 1.66; 95% CI, 1.47-1.87), stage II (HR, 1.52; 95% CI, 1.35-1.72), and stage III (HR, 1.32; 95% CI, 1.16-1.51) disease were associated with an increased likelihood of RTW in the fifth year after diagnosis. Kaplan-Meier survival analysis demonstrated better survival for the RTW group versus the non-RTW group in patients with stage III and IV oral cancer (P < .001). The fully adjusted HR indicated that the RTW group had significantly better outcomes than the non-RTW group in all-cause mortality (P < .001; HR, 0.36; 95% CI, 0.33-0.39).
CONCLUSIONS: Sociodemographic and medical factors affect the RTW of cancer survivors. RTW may have a beneficial effect on survival of patients with oral cancer.
© 2019 American Cancer Society.

Entities:  

Keywords:  cancer stage; cohort study; oral cancer; return to work; survival outcome

Year:  2019        PMID: 31809559     DOI: 10.1002/cncr.32643

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Return to work in head and neck cancer survivors: its relationship with functional, psychological, and disease-treatment factors.

Authors:  Pi-Ling Tsai; Chen-Ping Wang; Yuan-Yuan Fang; Yen-Ju Chen; Shu-Ching Chen; Min-Ru Chen; Jenq-Yuh Ko; Jiu-Jenq Lin; Pei-Jen Lou; Yeur-Hur Lai
Journal:  J Cancer Surviv       Date:  2022-07-28       Impact factor: 4.062

2.  Changes after cancer diagnosis and return to work: experience of Korean cancer patients.

Authors:  Ka Ryeong Bae; Juhee Cho
Journal:  BMC Cancer       Date:  2021-01-21       Impact factor: 4.430

3.  Clinical significance and immune landscapes of stemness-related and immune gene set-based signature in oral cancer.

Authors:  Xian Lin; Xiongzhou Zheng; Baihua Yang; Jian Chen; Qin Xu; Qingwen Wang
Journal:  Clin Transl Med       Date:  2021-02

4.  Return to work following laparoscopic-assisted resection or open resection for rectal cancer: Findings from AlaCaRT-Australasian Laparoscopic Cancer of the Rectum Trial.

Authors:  Chi Kin Law; Kate Brewer; Chris Brown; Kate Wilson; Lisa Bailey; Wendy Hague; John R Simes; Andrew Stevenson; Michael Solomon; Rachael L Morton
Journal:  Cancer Med       Date:  2020-12-06       Impact factor: 4.452

5.  Life expectancy estimations and determinants of return to work among cancer survivors over a 7-year period.

Authors:  Wei-Liang Chen; Yuan-Yuei Chen; Wei-Te Wu; Ching-Liang Ho; Chung-Ching Wang
Journal:  Sci Rep       Date:  2021-06-18       Impact factor: 4.379

6.  "This Graft-vs.-Host Disease Determines My Life. That's It."-A Qualitative Analysis of the Experiences and Needs of Allogenic Hematopoietic Stem Cells Transplantation Survivors in Germany.

Authors:  Mira Parisek; Julika Loss; Ernst Holler; Anna Barata; Daniela Weber; Matthias Edinger; Daniel Wolff; Helene Schoemans; Anne Herrmann
Journal:  Front Public Health       Date:  2021-07-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.